Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.21.2
Commitments and Contingencies (Details) - USD ($)
3 Months Ended 9 Months Ended
Jul. 27, 2021
Jul. 01, 2021
Mar. 28, 2021
Aug. 25, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Oct. 09, 2020
Commitments and Contingencies [Line Items]                    
Rent expense         $ 9,162 $ 14,174 $ 64,555 $ 32,076    
Percentage of company's annual requirements       100.00%            
Allowance for doubtful accounts                 $ 257,463  
Accrued settlement expense                 39,486,139  
Additional settlement liability     $ 21,365,641       21,365,641      
Number of shares issued upon exercise of warrants 1,833,596                  
Proceeds from issuance of common stock for exercise of warrant $ 9,186,316           16,699,489      
Prepaid expenses and other current assets         6,350,889   6,350,889   240,352  
GEM Warrant [Member]                    
Commitments and Contingencies [Line Items]                    
Warrant issued     3,329,812              
Exercise price of warrant     $ 3.19              
Warrants to purchase shares     1,496,216              
Warrants to purchase shares, amount     $ 7,500,018              
Warrants expire period     The GEM Warrant were valid for a period of three years from the date NeuroRx’s stock is listed for trading on a national securities exchange or consummation of a reverse merger transaction of the type contemplated by the Merger Agreement.              
Accrued settlement expense                 $ 39,486,139  
Reimbursements from Relief Therapeutics Holding AG                    
Commitments and Contingencies [Line Items]                    
Reimbursable expenses             13,800,000      
Payment to related party             $ 10,900,000      
Phase II Inhaled clinical trial of Aviptadil                    
Commitments and Contingencies [Line Items]                    
Research commitments   $ 7,400,000                
GEM Share Subscription Facility Agreement                    
Commitments and Contingencies [Line Items]                    
Share subscription agreement term             3 years      
Share subscription value         95,600,000   $ 95,600,000      
Commitment fee             1,900,000      
Polypeptide [Member]                    
Commitments and Contingencies [Line Items]                    
Purchase commitments                   $ 5,255,000
Prepaid expenses and other current assets         1,407,500   1,407,500      
Sponsored Research Agreement [Member]                    
Commitments and Contingencies [Line Items]                    
Research commitments             399,320      
Research commitments paid         $ 90,112   $ 216,269